BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Boiardi L, Catanoso M, Pipitone N, Cassone G, Girolimetto N, Croci S, Cimino L, Gradellini F, Beltrami M, Di Lernia V, Dolci G, Massari M, Marata AM, Costantini M, Giorgi Rossi P. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Ann Rheum Dis 2020;79:986-8. [PMID: 32467245 DOI: 10.1136/annrheumdis-2020-217903] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Lauper K, Bijlsma JWJ, Burmester GR. Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic. Ann Rheum Dis 2021;80:26-30. [PMID: 33055081 DOI: 10.1136/annrheumdis-2020-219217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Esatoglu SN, Tascilar K, Babaoğlu H, Bes C, Yurttas B, Akar S, Pehlivan O, Akleylek C, Tecer D, Seyahi E, Yuce-Inel T, Alpay-Kanitez N, Bodakci E, Tekgoz E, Colak S, Bolek EC, Koca SS, Kalyoncu U, Icacan OC, Ugurlu S, Oz HE, Hamuryudan V, Hatemi G; Turkish Society for Rheumatology COVID-19 Registry Investigators. COVID-19 Among Patients With Inflammatory Rheumatic Diseases. Front Immunol 2021;12:651715. [PMID: 33936073 DOI: 10.3389/fimmu.2021.651715] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Stradner MH, Dejaco C, Zwerina J, Fritsch-Stork RD. Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic. Front Med (Lausanne) 2020;7:562142. [PMID: 33154972 DOI: 10.3389/fmed.2020.562142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Tam LS, Tanaka Y, Handa R, Li Z, Lorenzo JP, Louthrenoo W, Hill C, Pile K, Robinson PC, Dans LF, Hsu LY, Lee SM, Cho J, Hasan ATMT, Salim B, Samreen S, Shaharir SS, Wong P, Chau J, Danda D, Haq SA. Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. Int J Rheum Dis 2021;24:733-45. [PMID: 33945214 DOI: 10.1111/1756-185X.14124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Kahlmann V, Manansala M, Moor CC, Shahrara S, Wijsenbeek MS, Sweiss NJ. COVID-19 infection in patients with sarcoidosis: susceptibility and clinical outcomes. Curr Opin Pulm Med 2021;27:463-71. [PMID: 34397613 DOI: 10.1097/MCP.0000000000000812] [Reference Citation Analysis]
6 Manansala M, Baughman R, Novak R, Judson M, Sweiss N. Management of immunosuppressants in the era of coronavirus disease-2019. Curr Opin Pulm Med 2021;27:176-83. [PMID: 33779588 DOI: 10.1097/MCP.0000000000000770] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin Infect Dis. 2021;72:340-350. [PMID: 33501974 DOI: 10.1093/cid/ciaa863] [Cited by in Crossref: 95] [Cited by in F6Publishing: 99] [Article Influence: 95.0] [Reference Citation Analysis]
8 Soldevila-Domenech N, Tío L, Llorente-Onaindia J, Martín-García E, Nebot P, de la Torre R, Gurt A, Maldonado R, Monfort J; Covidmar Study Group. COVID-19 Incidence in Patients With Immunomediated Inflammatory Diseases: Influence of Immunosuppressant Treatments. Front Pharmacol 2020;11:583260. [PMID: 33519443 DOI: 10.3389/fphar.2020.583260] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Cook C, Cox H, Fu X, Zhang Y, Stone JH, Choi HK, Wallace ZS. Perceived Risk and Associated Shielding Behaviors in Patients With Rheumatoid Arthritis During the Coronavirus 2019 Pandemic. ACR Open Rheumatol 2021;3:834-41. [PMID: 34498436 DOI: 10.1002/acr2.11340] [Reference Citation Analysis]
10 Conway R, Konig MF, Graef ER, Webb K, Yazdany J, Kim AHJ. Inflammatory arthritis in patients with COVID-19. Transl Res 2021;232:49-59. [PMID: 33626415 DOI: 10.1016/j.trsl.2021.02.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wang Q, Liu J, Shao R, Han X, Su C, Lu W. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis. Rheumatol Int 2021;41:851-61. [PMID: 33687528 DOI: 10.1007/s00296-021-04803-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
12 Spinella A, Magnani L, De Pinto M, Marvisi C, Parenti L, Bajocchi G, Salvarani C, Mascia MT, Giuggioli D. Management of Systemic Sclerosis Patients in the COVID-19 Era: The Experience of an Expert Specialist Reference Center. Clin Med Insights Circ Respir Pulm Med 2021;15:11795484211001349. [PMID: 33795941 DOI: 10.1177/11795484211001349] [Reference Citation Analysis]
13 Gamboa-Cárdenas RV, Barzola-Cerrón S, Toledo-Neira D, Reátegui-Sokolova C, Pimentel-Quiroz V, Zevallos-Miranda F, Alarcón GS, Ugarte-Gil M. Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up. Clin Rheumatol 2021. [PMID: 34189675 DOI: 10.1007/s10067-021-05833-1] [Reference Citation Analysis]
14 Kroon FPB, Najm A, Alunno A, Schoones JW, Landewé RBM, Machado PM, Navarro-Compán V. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. Ann Rheum Dis 2021:annrheumdis-2021-221575. [PMID: 34876462 DOI: 10.1136/annrheumdis-2021-221575] [Reference Citation Analysis]
15 Salvarani C, Mancuso P, Gradellini F, Viani N, Pandolfi P, Reta M, Carrozzi G, Sandri G, Bajocchi G, Galli E, Muratore F, Boiardi L, Pipitone N, Cassone G, Croci S, Marata AM, Costantini M, Giorgi Rossi P. Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. Arthritis Rheumatol 2021;73:48-52. [PMID: 32767527 DOI: 10.1002/art.41475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 So H, Mok CC, Yip RML. The Hong Kong Society of Rheumatology Consensus Recommendations for COVID-19 Vaccination in Adult Patients with Autoimmune Rheumatic Diseases. Journal of Clinical Rheumatology and Immunology 2021;21:7-14. [DOI: 10.1142/s2661341721400010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Brito-Zerón P, Gracia-Tello B, Robles A, Alguacil A, Bonet M, De-Escalante B, Noblejas-Mosso A, Gómez-de-la-Torre R, Akasbi M, Pérez-de-Lis M, Pérez-Alvarez R, Ramos-Casals M, On Behalf Of The SarcoGEAS-Semi Registry. Characterization and Outcomes of SARS-CoV-2 Infection in Patients with Sarcoidosis. Viruses 2021;13:1000. [PMID: 34071924 DOI: 10.3390/v13061000] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G, Amor S. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 2020;202:149-61. [PMID: 32671831 DOI: 10.1111/cei.13495] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 37.5] [Reference Citation Analysis]
19 Thanou A, Sawalha AH. SARS-CoV-2 and Systemic Lupus Erythematosus. Curr Rheumatol Rep 2021;23:8. [PMID: 33511495 DOI: 10.1007/s11926-020-00973-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Shenoy P, Ahmed S, Shanoj KC, Shenoy V, Damodaran D, Menon AR, Alias B, SanjoSaijan, Devakumar D, Babu ASS. Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease. Clin Rheumatol 2021. [PMID: 34155573 DOI: 10.1007/s10067-021-05801-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Kasap Cuceoglu M, Batu ED, Bilginer Y, Özen S. COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study. Ann Rheum Dis 2020:annrheumdis-2020-218341. [PMID: 32632034 DOI: 10.1136/annrheumdis-2020-218341] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Mintoff D, Benhadou F. Guselkumab does not appear to influence the IgG antibody response to SARS-CoV-2. Dermatol Ther 2021;:e15246. [PMID: 34865295 DOI: 10.1111/dth.15246] [Reference Citation Analysis]
23 Lucio Liberato N, De Monte A, Caravella G. Tocilizumab in severe COVID-19. Arch Med Sci 2020;16:1457-8. [PMID: 33224347 DOI: 10.5114/aoms.2020.97411] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Benfaremo D, Perini L, Marconi V, Luchetti MM, Gabrielli A. Disease course in patients with systemic autoimmune diseases: insights on the safety of immunosuppression during the SARS-CoV-2 outbreak in Italy. Eur J Intern Med 2021;83:90-2. [PMID: 33092952 DOI: 10.1016/j.ejim.2020.10.010] [Reference Citation Analysis]
25 Ayala Gutiérrez MDM, Rubio-Rivas M, Romero Gómez C, Montero Sáez A, Pérez de Pedro I, Homs N, Ayuso García B, Cuenca Carvajal C, Arnalich Fernández F, Beato Pérez JL, Vargas Núñez JA, Letona Giménez L, Suárez Fernández C, Méndez Bailón M, Tuñón de Almeida C, González Moraleja J, de Guzmán García-Monge M, Helguera Amezua C, Fidalgo Montero MDP, Giner Galvañ V, Gil Sánchez R, Collado Sáenz J, Boixeda R, Ramos Rincón JM, Gómez Huelgas R, On Behalf Of The Semi-Covid-Network. Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry. J Clin Med 2021;10:1844. [PMID: 33922777 DOI: 10.3390/jcm10091844] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Carter-Timofte ME, Jørgensen SE, Freytag MR, Thomsen MM, Brinck Andersen NS, Al-Mousawi A, Hait AS, Mogensen TH. Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. Front Immunol 2020;11:1606. [PMID: 32695122 DOI: 10.3389/fimmu.2020.01606] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
27 Maslennikov R, Ivashkin V, Vasilieva E, Chipurik M, Semikova P, Semenets V, Russkova T, Levshina A, Grigoriadis D, Magomedov S, Efremova I, Dzhakhaya N. Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19). Eur Cytokine Netw 2021;32:8-14. [PMID: 34346869 DOI: 10.1684/ecn.2021.0463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Shin YH, Shin JI, Moon SY, Jin HY, Kim SY, Yang JM, Cho SH, Kim S, Lee M, Park Y, Kim MS, Won HH, Hong SH, Kronbichler A, Koyanagi A, Jacob L, Smith L, Lee KH, Suh DI, Lee SW, Yon DK. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol 2021. [PMID: 34179832 DOI: 10.1016/S2665-9913(21)00151-X] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
29 Ferri C, Giuggioli D, Raimondo V, Fallahi P, Antonelli A; COVID-19 & ASD Italian Study Group. COVID-19 in Italian patients with rheumatic autoimmune systemic diseases. Ann Rheum Dis 2020:annrheumdis-2020-219113. [PMID: 33055077 DOI: 10.1136/annrheumdis-2020-219113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Felten R, Scherlinger M, Guffroy A, Poindron V, Meyer A, Giannini M, Korganow AS, Sordet C, Chatelus E, Javier RM, Meyer A, Pijnenburg L, Kleinmann JF, Gottenberg JE, Sibilia J, Martin T, Arnaud L. Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France. Arthritis Res Ther 2021;23:188. [PMID: 34256812 DOI: 10.1186/s13075-021-02565-0] [Reference Citation Analysis]
31 Tana C, Schiavone C, Cipollone F, Giamberardino MA. Management Issues of Sarcoidosis in the Time of Coronavirus Disease 2019. Chest 2021;159:1306-7. [PMID: 33678261 DOI: 10.1016/j.chest.2020.09.267] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
32 Marques CDL, Kakehasi AM, Pinheiro MM, Mota LMH, Albuquerque CP, Silva CR, Santos GPJ, Reis-Neto ET, Matos P, Devide G, Dantas A, Giorgi RD, Marinho AO, Valadares LDA, Melo AKG, Ribeiro FM, Ferreira GA, Santos FPS, Ribeiro SLE, Andrade NPB, Yazbek MA, Souza VA, Paiva ES, Azevedo VF, Freitas ABSB, Provenza JR, Toledo RA, Fontenelle S, Carneiro S, Xavier R, Pileggi GCS, Reis APMG. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. RMD Open 2021;7:e001461. [PMID: 33510041 DOI: 10.1136/rmdopen-2020-001461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
33 Ammitzbøll C, Thomsen MK, Andersen JB, Bartels LE, Hermansen MF, Johannsen AD, Mistegaard CE, Mikkelsen S, Vils SR, Erikstrup C, Hauge EM, Troldborg A. COVID-19 Vaccination in Patients with Rheumatic Diseases Leads to a High Seroconversion Rate and Reduced Self-Imposed Isolation and Shielding Behavior. Mod Rheumatol 2022:roac069. [PMID: 35860843 DOI: 10.1093/mr/roac069] [Reference Citation Analysis]
34 Jung Y, Kwon M, Choi HG. Association between previous rheumatoid arthritis and COVID-19 and its severity: a nationwide cohort study in South Korea. BMJ Open 2021;11:e054753. [PMID: 34620675 DOI: 10.1136/bmjopen-2021-054753] [Reference Citation Analysis]